- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2015–2025 · research · R01
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2021 · research · R35
Dissecting and Targeting Deregulated Mitochondrial Apoptosis in Human Cancer
Loren David Walensky · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Elucidating and overcoming endocrine resistance driven by ESR1 mutations
Rinath M. Jeselsohn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2022 · research · R35
How do genome alterations cause human lung cancer?
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2028 · research · R35
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma
Brian Crompton · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Stress response networks in HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2028 · research · R35
NKX2-1 Enhancer Amplification and Lineage Addiction in Lung Adenocarcinoma
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R37
Biochemical Mechanism of HIV DNA Integration
Alan N. Engelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2025 · research · R01
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Genetic evolution of glioblastomas during radiation and temozolomide therapy
Rameen Beroukhim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Therapeutic targeting of Fibroblast Growth Factor Receptors in Squamous Cancers
Adam Joel Bass · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · cooperative agreement · U24
Quantitative Radiomics System Decoding the Tumor Phenotype
Hugo Aerts · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · cooperative agreement · U54
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies
Eric C. Holland · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Testing the role of BATF as a pioneer transcription factor in effector T cells
William Nicholas Haining · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Testing the role of BATF as a pioneer transcription factor in effector T cells
Cigall Kadoch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2026 · research · R01
Targeting the cytokine circuitry of KRAS-driven lung cancer
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Studies of IGHV Germline Gene Polymorphism, Utilization & Shifting for Seasonal Influenza Vaccine Induced Broadly Neutralizing Antibody Responses
Wayne A. Marasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Precision Medicine For Pediatric Low-Grade Gliomas
Daphne A. Haas-Kogan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2022 · research · R35
Targeting intratumor heterogeneity in breast cancer
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2021 · research · R01
The function of cyclin C in tumorigenesis
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2022 · research · R35
Targeting intratumor heterogeneity in breast cancer
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Determining the mutational landscape of circulating multiple myeloma cells
Jens G Lohr · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Identifying the roles of DNA rewinding enzymes on maintaining genome stability
Timur Yusufzai · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Genetic evolution of glioblastomas during radiation and temozolomide therapy
Rameen Beroukhim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · cooperative agreement · U54
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies
Eric C. Holland · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemia
Birgit Knoechel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Identifying the roles of DNA rewinding enzymes on maintaining genome stability
Timur Yusufzai · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · cooperative agreement · U01
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors
Joe W. Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2021 · cooperative agreement · U54
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies
Eric C. Holland · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Determining the mutational landscape of circulating multiple myeloma cells
Jens G Lohr · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2026 · research · R01
Evolution of gliomas during treatment and resistance
Rameen Beroukhim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R37
Biochemical Mechanism of HIV DNA Integration
Alan N. Engelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2021 · research · R01
Validating the eCyPA/CD147 signaling complex for myeloma therapy
Ruben D Carrasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2021 · research · R01
Precision Medicine For Pediatric Low-Grade Gliomas
Daphne A. Haas-Kogan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Studies of IGHV Germline Gene Polymorphism, Utilization & Shifting for Seasonal Influenza Vaccine Induced Broadly Neutralizing Antibody Responses
Wayne A. Marasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Defining the epigenetic landscape in human prostate cancer
Myles A Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Testing the role of BATF as a pioneer transcription factor in effector T cells
William Nicholas Haining · Dana-Farber Cancer Institute · funded by National Institutes of Health
